Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829678 | 0.93 | MRGPRX4 (0.48) | MAOBMRGPRX4NR4A2NPC1RAB9A | |
| SCHEMBL14829599 | 0.92 | MRGPRX4 (0.47) | MAOBMRGPRX4NR4A2PARP10EGFR | |
| SCHEMBL14829500 | 0.91 | MAOB (0.48) | MAOBMRGPRX4NR4A2PARP10NPC1 | |
| SCHEMBL14829711 | 0.91 | PTGER1 (0.45) | MRGPRX4NPC1RAB9A | |
| SCHEMBL14830236 | 0.90 | MAOB (0.47) | MAOBMRGPRX4NR4A2PARP10EGFR | |
| SCHEMBL14829709 | 0.88 | MAOB (0.47) | MAOBMRGPRX4NR4A2 | |
| SCHEMBL14829685 | 0.88 | MAOB (0.48) | MAOBMRGPRX4NR4A2PARP10EGFR | |
| SCHEMBL14829682 | 0.87 | EGFR (0.42) | MAOBMRGPRX4NR4A2PARP10EGFR | |
| SCHEMBL14829669 | 0.87 | MAOB (0.46) | MAOBMRGPRX4NR4A2PARP10EGFR | |
| SCHEMBL14829543 | 0.85 | MRGPRX4 (0.49) | MAOBMRGPRX4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | claimed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, RAF1 | MAOB 183/4885MRGPRX4 2329/4885NR4A2 2560/4885 |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAOB 815/4885MRGPRX4 2298/4885NR4A2 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.